WEED is an early-stage cannabis research and bio-pharmaceutical holding company with no commercial products and no meaningful revenue. The company's core activity is a multi-phase Cannabis Genomic Study, conducted through its subsidiary Sangre AT, which aims to sequence and classify the full cannabis genome and develop patentable cannabis strains optimized for medicinal use. A pilot study of 30 cannabis cultivars was completed at the University of Texas-Galveston; further phases are contingent on raising additional capital, which the company has not yet secured. WEED also holds a seedbank of over 250 cannabis and hemp strains — including rare Landrace varieties like Panama Red and Acapulco Gold — acquired through its 2022 purchase of Hempirical Genetics. The company's long-term revenue model centers on IP licensing and patent royalties, pharmaceutical-grade cannabinoid product sales, and real estate development through a 44-acre property in Portland, New York intended for hemp and infused beverage operations. WEED also entered a partnership in late 2025 to explore blockchain-based digital tokens aimed at addressing banking and supply chain challenges in the cannabis industry. The company funds itself through securities offerings and has no committed path to revenue; all research phases, clinical trials, and manufacturing plans depend on future capital raises.